Sökning: onr:"swepub:oai:DiVA.org:uu-183751" >
Tacrolimus-Based, S...
Tacrolimus-Based, Steroid-Free Regimens in Renal Transplantation : 3-Year Follow-Up of the ATLAS Trial
-
Kraemer, Bernhard K. (författare)
-
Klinger, Marian (författare)
-
Vitko, Stefan (författare)
-
visa fler...
-
Glyda, Maciej (författare)
-
Midtvedt, Karsten (författare)
-
Stefoni, Sergio (författare)
-
Citterio, Franco (författare)
-
Pietruck, Frank (författare)
-
Squifflet, Jean-Paul (författare)
-
Segoloni, Giuseppe (författare)
-
Krueger, Bernd (författare)
-
Sperschneider, Heide (författare)
-
Banas, Bernhard (författare)
-
- Bäckman, Lars (författare)
- Uppsala universitet,Transplantationskirurgi
-
Weber, Markus (författare)
-
Carmellini, Mario (författare)
-
Perner, Ferenc (författare)
-
Claesson, Kerstin (författare)
-
Marcinkowski, Wojciech (författare)
-
Ostrowski, Marek (författare)
-
Senatorski, Grzegorz (författare)
-
- Nordstrom, Johan (författare)
- Karolinska Institutet
-
Salmela, Kaija (författare)
-
visa färre...
-
(creator_code:org_t)
- 2012
- 2012
- Engelska.
-
Ingår i: Transplantation. - 0041-1337 .- 1534-6080. ; 94:5, s. 492-498
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background. Long-term use of corticosteroids is associated with considerable morbidity, including cardiovascular and metabolic adverse effects. Methods. This study evaluated the long-term efficacy and safety of two steroid-free regimens compared with a triple immunosuppressive therapy in renal transplant recipients. This was a 3-year follow-up to a 6-month, open-label, randomized, multicenter study. Results. Data from 3 years were available for 421 (93.3%) of 451 patients in the original intent-to-treat population (143 tacrolimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/steroids [triple therapy]). In the time interval from 6 months to 3 years after transplantation, the incidence of biopsy-proven acute rejection was low and similar (Tac/Bas, 2.1%; Tac/MMF, 2.2%; triple therapy, 2.2%); Most rejection episodes occurred during the first 6 months of the study. Graft survival was high (Kaplan-Meier estimates: 92.7%, 92.5%, and 92.5%), as was patient survival (93.1%, 96.4%, and 97.0%). There were 10 graft losses (n=2, 4, and 4) and 12 patient deaths (n=5, 2, and 5). Renal function was well preserved throughout the study and similar between groups. There was a trend toward improved cardiovascular risk factors in the Tac/Bas group, including reduced total and low-density lipoprotein cholesterol and lower new-onset insulin use. There were no between-group differences in the incidence or type of adverse events. Conclusion. Higher rates of acute rejection early in treatment were seen with the steroid-free regimens, but this did not translate into poorer long-term outcomes, such as graft and patient survival and renal function. A trend for a more favorable cardiovascular risk profile was observed for steroid-free immunosuppression with Tac/Bas.
Nyckelord
- Tacrolimus
- Renal transplant
- Immunosuppression
- Steroid
- Long term
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kraemer, Bernhar ...
-
Klinger, Marian
-
Vitko, Stefan
-
Glyda, Maciej
-
Midtvedt, Karste ...
-
Stefoni, Sergio
-
visa fler...
-
Citterio, Franco
-
Pietruck, Frank
-
Squifflet, Jean- ...
-
Segoloni, Giusep ...
-
Krueger, Bernd
-
Sperschneider, H ...
-
Banas, Bernhard
-
Bäckman, Lars
-
Weber, Markus
-
Carmellini, Mari ...
-
Perner, Ferenc
-
Claesson, Kersti ...
-
Marcinkowski, Wo ...
-
Ostrowski, Marek
-
Senatorski, Grze ...
-
Nordstrom, Johan
-
Salmela, Kaija
-
visa färre...
- Artiklar i publikationen
-
Transplantation
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet